Keystone Law intellectual property partner Maureen Kelly has advised PrecisionLife, the combinatorial analytics company, on its strategic partnership agreement with Cyclica Inc., the drug-discovery company, to co-market and offer their complementary computational platforms as an integrated drug-discovery factory.

The companies will initially collaborate on up to 30 pharma and biotechnology drug-discovery programmes over the next two years. Together, they have capacity to advance a large number of innovative AI enhanced drug-discovery programs and build an industry pipeline of partnered R&D opportunities.

Dr Steve Gardner, CEO of PrecisionLife, said:

“Maureen’s expert guidance has once again proven to be instrumental in formalising our partnership with Cyclica. Her ongoing support and technical understanding of the life sciences sector makes a tremendous difference in being able to achieve our strategic aims.”

Commenting on the transaction, Maureen Kelly added:

“It has been a pleasure advising PrecisionLife on this exciting partnership and I look forward to seeing the combined development of new medicine using world-leading AI.”